drugset / Trial / NCT01678105
A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
Phase 2
Completed
21 enrolled
Ontario Clinical Oncology Group (OCOG)
Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a non-randomized, phase II, open label study of dovitinib in patients with progressive, recurrent and/or metastatic adenoid cystic carcinoma (ACC). The primary purpose of this study is to assess the anti-cancer effects of dovitinib in this population in order to evaluate whether dovitinib is worthy of further study in patients with progressive ACC.
Timeline
- Start
- 2012-11
- Primary completion
- 2015-09
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dovitinib | Small molecule | 500 mg | Oral |